SCHEMBL6157084

SCHEMBL6157084

Cc1nc(C)c(-c2ccnc(Nc3ccc(Cl)cc3)n2)s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 20/20 1.00
CDK4 P11802 15/20 0.79
AURKA O14965 5/20 0.79
CDK1 P06493 4/20 0.79
CDK7 P50613 4/20 0.79
CDK9 P50750 4/20 0.79
AURKB Q96GD4 4/20 0.79
PLK1 P53350 2/20 0.77
CCNE1 P24864 2/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12589637 0.89 CDK2 (0.82) CDK2CDK4AURKACDK1CDK7
SCHEMBL6156894 0.88 CDK2 (0.80) CDK2CDK4AURKACDK1CDK7
SCHEMBL2073680 0.87 CDK2 (0.78) CDK2CDK4AURKACDK1CDK7
SCHEMBL6157812 0.87 CDK2 (0.79) CDK2CDK4AURKACDK1CDK7
SCHEMBL6160035 0.87 CDK2 (1.00) CDK2CDK4AURKACDK1CDK7
SCHEMBL6158693 0.87 CDK2 (0.79) CDK2CDK4AURKACDK1CDK7
SCHEMBL2289103 0.87 CDK2 (1.00) CDK2CDK4AURKACDK1CDK7
SCHEMBL2075942 0.87 CDK2 (1.00) CDK2CDK4AURKACDK1CDK7
SCHEMBL2284091 0.86 CDK2 (1.00) CDK2CDK4AURKACDK1CDK7
SCHEMBL2288706 0.86 CDK2 (0.78) CDK2CDK4AURKACDK1CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4576552-A1 POWER CONVERTER Delta Electronics, Inc. (TW) 2025-06-25 EP claimed
CN-119967671-A Afterglow eliminating circuit 浙江凯耀照明有限责任公司 2025-05-09 CN claimed
CN-119909064-A Cystamine derivative or salt thereof and application thereof in preparation of medicines with antioxidation effect 北京大学深圳研究生院 2025-05-02 CN claimed
US-20250091966-A1 Silicate Solubilizing Streptomyces Sp. CS13-6 and Uses Thereof INSTITUTE OF BIOLOGY, HEBEI ACADEMY OF SCIENCE (CN) 2025-03-20 US claimed
EP-4517753-A1 METADATA AND USER DATA STORAGE IN DIFFERENT BANKS Samsung Electronics Co., Ltd (KR) 2025-03-05 EP claimed
US-20240251664-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2024-07-25 US claimed
CN-113852373-B Successive approximation type analog-to-digital converter with pipeline domino structure 西安电子科技大学 2024-07-12 CN claimed
WO-2024051151-A1 SILICON-RELEASING STREPTOMYCES CS13-6 AND USE THEREOF 河北省科学院生物研究所 2024-03-14 WO claimed
CN-117070375-B Composite microbial agent and application thereof in ecological restoration of soil 河北省科学院生物研究所 2024-02-06 CN claimed
CN-117070375-A Composite microbial agent and application thereof in ecological restoration of soil 河北省科学院生物研究所 2023-11-17 CN claimed
CN-216600136-U Two-way color temperature switching equalization circuit 宁波凯耀电器制造有限公司 2022-05-24 CN claimed
CN-216356471-U Power supply conversion circuit for high noise suppression audio conversion controller 西安赛普特信息科技有限公司 2022-04-19 CN claimed
US-20050288307-A1 Anti-viral compounds CYCLACEL LIMITED (GB) 2005-12-29 US claimed
EP-1581231-A1 ANTI-VIRAL COMPOUNDS Cyclacel Limited (GB) 2005-10-05 EP claimed
WO-2004043467-A1 ANTI-VIRAL COMPOUNDS CYCLACEL LIMITED (GB) 2004-05-27 WO claimed
US-20030149057-A1 Anti-cancer compounds CYCLACEL LIMITED (GB) 2003-08-07 US claimed
US-6531479-B2 Anticancer agents, skin disorders CYCLACEL LIMITED (GB) 2003-03-11 US claimed
EP-1274705-A1 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2003-01-15 EP claimed
US-20020019404-A1 Anti-cancer compounds CYCLACEL LIMITED (GB) 2002-02-14 US claimed
WO-2001072745-A1 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2001-10-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019404-A1 Anti-cancer compounds CDK3, CDK2, CDK4 CDK2 2/4885CDK4 3/4885AURKA 85/4885
US-20030149057-A1 Anti-cancer compounds CDK3, CDK2, CDK4 CDK2 2/4885CDK4 3/4885AURKA 85/4885
US-20240251664-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME NES, NFE2L2, NUCB2 CDK2 1219/4885CDK4 2213/4885AURKA 1164/4885
US-20050288307-A1 Anti-viral compounds MAVS, HAVCR2, EIF2AK2 CDK2 205/4885CDK4 477/4885AURKA 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.